ArticleJournal of cell science2026
A high-yield protein expression platform in the unicellular red alga Cyanidioschyzon merolae.
Article in Journal of cell science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The production of engineered proteins in transgenic cells is widely used in research, medicine and industry. However, conventional cell-based production systems still face challenges in cost, scalability and biosafety. Here, we present a recombinant protein expression platform with simplified purification based on the photosynthetic unicellular red alga Cyanidioschyzon merolae, which can be cultivated under highly acidic conditions using only inorganic nutrients, air, water and light. We first identified a promoter that drives high-level constitutive gene expression throughout the cell cycle, resulting in substantial mRNA accumulation in C. merolae. A stable transformant expressing His-tagged mVenus under the control of this promoter accumulated the recombinant protein to more than 1% of total soluble protein. The simple cellular architecture of C. merolae, including the absence of a cell wall, enables efficient protein extraction via a single freeze-thaw cycle, followed by purification using immobilized metal affinity chromatography (IMAC), yielding ∼13.9 mg of functional recombinant protein per gram of total soluble protein. Owing to its low cost, scalability, operational simplicity and minimal risk of contamination, this Cyanidioschyzon-based platform offers a practical and promising approach to recombinant protein production in a photosynthetic eukaryote.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.